SR One Capital Management LP bought a new position in enGene Holdings Inc. (NASDAQ:ENGN – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 747,750 shares of the company’s stock, valued at approximately $1,293,607,000. enGene comprises about 0.1% of SR One Capital Management LP’s investment portfolio, making the stock its 15th biggest holding. SR One Capital Management LP owned 1.12% of enGene at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Cresset Asset Management LLC bought a new position in shares of enGene in the second quarter worth about $36,000. Paloma Partners Management Co bought a new stake in shares of enGene during the second quarter valued at approximately $38,000. Raymond James Financial Inc. grew its stake in shares of enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after purchasing an additional 7,932 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of enGene in the fourth quarter valued at approximately $121,000. Finally, Millennium Management LLC increased its holdings in shares of enGene by 57.3% in the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after purchasing an additional 7,472 shares in the last quarter. Institutional investors and hedge funds own 64.16% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on the company. Oppenheimer lowered enGene from an “outperform” rating to a “market perform” rating in a research note on Friday, May 8th. Piper Sandler lowered enGene from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $7.00 to $4.00 in a research report on Friday, May 8th. Wells Fargo & Company reissued an “equal weight” rating and set a $2.00 price objective (down from $25.00) on shares of enGene in a report on Friday, May 8th. Weiss Ratings restated a “sell (e+)” rating on shares of enGene in a research report on Wednesday, August 12th. Finally, Citigroup downgraded shares of enGene from a “market outperform” rating to a “market perform” rating in a research report on Friday, May 8th. Four investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $11.05.
enGene Trading Up 0.6%
Shares of NASDAQ:ENGN opened at $1.78 on Friday. The company’s 50-day moving average price is $1.80 and its two-hundred day moving average price is $4.76. enGene Holdings Inc. has a one year low of $1.40 and a one year high of $12.25. The company has a debt-to-equity ratio of 0.10, a current ratio of 12.57 and a quick ratio of 12.57. The stock has a market capitalization of $119.24 million, a PE ratio of -0.82 and a beta of -0.28.
enGene (NASDAQ:ENGN – Get Free Report) last released its earnings results on Monday, June 15th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.05. During the same quarter in the prior year, the firm earned $0.51 earnings per share. On average, equities analysts forecast that enGene Holdings Inc. will post -1.84 EPS for the current fiscal year.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
See Also
- Five stocks we like better than enGene
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Want to see what other hedge funds are holding ENGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for enGene Holdings Inc. (NASDAQ:ENGN – Free Report).
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
